Piperacillin/Tazobactam

Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsPiperacillin/Tazobactam2.25-4.5g IV Q12HAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
518/30075-90/650.8-1.5/13.3-5.1/1730/220.18-0.30/0.2146.3-78.2/94.610-65/37-39 (low flux)

References:

  • De Schepper P, Tjandramaga T, Mullie A et al. Comparative pharmacokinetics of piperacillin in normals and in patients with renal failure. The Journal of antimicrobial chemotherapy 1982; 9(Suppl B), 49-57.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00319, http://www.drugbank.ca/drugs/DB01606
  • Francke E, Appel G, Neu H. Pharmacokinetics of Intravenous Piperacillin in Patients Undergoing Chronic Hemodialysis. Antimicrobial agents and chemotherapy 1979; 16(6), 788-92.
  • Giron J, Meyers B, Hirschman S, Srulevitch E. Pharmacokinetics of Piperacillin in Patients with Moderate Renal Failure and in Patients Undergoing Hemodialysis. Antimicrobial agents and chemotherapy 1981; 19(2), 279-84.
  • Halstenson C, Wong M, Johnson C et al. Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment. The Journal of Clinical Pharmacology 1994; 34, 1208-18.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Johnson C, Halstenson C, Kelloway J et al. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clinical pharmacology and therapeutics 1992; 51(1), 32-41.
  • Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
  • Thompson M, Russo E, Matsen J, Atkin-thor E. Piperacillin Pharmacokinetics in Subjects with Chronic Renal Failure. Antimicrobial agents and chemotherapy 1981; 19(3), 450-4.